The leader in the business of psychedelics, Microdose is taking the next step in top-notch industry events with Wonderland 2022. Pulling off such a massive undertaking wouldn’t be possible without the support of our sponsors, they are crucial to both the Wonderland event and the future of the psychedelic medicine industry.
So it’s an honor for Microdose to announce Algernon Pharmaceuticals as the Headline Sponsor for Wonderland: Miami 2022.
Algernon’s CEO, Christopher J. Moreau, will deliver two keynote addresses:
- Business Session Keynote November 4th, 1:00 pm EST
- Science Session Keynote November 5th 2:00 pm EST
“We are delighted to welcome our friends at Algernon Pharmaceuticals as a sponsor of the conference and to have them involved with our programs,” said Patrick Moher, President of Microdose Psychedelic Insights. “Wonderland Miami is a one-of-a-kind event, and we are very pleased to continue our collaboration with Algernon Pharmaceuticals as an official headline sponsor.”
Algernon’s work in the psychedelic medicine space
Algernon has established a clinical research program for the treatment of stroke focused on AP-188 (“N,N-Dimethyltryptamine or DMT”), a known psychedelic compound that is part of the tryptamine family (other drugs in the tryptamine family include psilocybin and psilocin). Algernon plans to be the first company globally to investigate DMT as a possible treatment for stroke and is planning to begin a Phase 1 clinical trial beginning in Q4, 2022.
The company’s decision to investigate DMT and move it into human trials for stroke is based on multiple independent, positive preclinical studies demonstrating that DMT helps promote neurogenesis as well as structural and functional neural plasticity. These are key factors involved in the brain’s ability to form and reorganize synaptic connections, which are needed for healing following a brain injury.
The Company has now completed its intravenous formulation (“IVF”) that will be used in the Phase 1 DMT study. The formulation was developed by the Centre for Human Drug Research (“CHDR”) and its affiliated pharmacy at the Leiden University Medical Center in the Netherlands. The company has applied for ethics and clinical trial approval and is expecting to have a response shortly.
“We are delighted to be the headline sponsor for the Wonderland 2022 event and have the opportunity to build a greater awareness of Algernon and our DMT stroke research program within the many different facets of the psychedelic medicine world,” said Christopher J. Moreau, CEO, Algernon Pharmaceuticals.
